Press & events

What's happening?

Stay updated on our latest news and events.

Displaying 61 - 70 of 77

Insights

With US serialisation requirements about to come into force and EU regulations on the horizon, more and more businesses are considering what track and trace could mean for them beyond compliance.

Insights

Demand for outsourced contract manufacturing in the pharmaceutical industry continues to grow, but what does it take to be a trusted partner?

Insights

The current pharmaceutical industry landscape creates some interesting opportunities for CDMOs to grow and develop.

Insights

In the last ten years, the contract manufacturing sector has experienced some major changes as a result of consolidation, increasing price pressures and evolving customer expectations.

Insights

Amjad Alhalaweh, one of our formulation scientists at Recipharm, took part in the in-Pharma Technologist Drug Delivery online conference on Thursday 20th April, 2017.

Insights

As the need to manufacture more challenging drugs for smaller patient populations increases so too does the demand for aseptic manufacturing.

Highly potent oncology drugs and injectables are driving the demand for CDMOs to meet the stringent regulatory requirements surrounding the manufacture of sterile products.  

Insights

During the discovery and early stages of drug development the pharmacology, pharmacokinetics and toxicology of a compound are evaluated using a simple liquid formulation. However, low aqueous solubility can prove to be a major obstacle when it comes to the development of liquid formulations, so selecting the right excipients to help solubilise them is vital.

Insights

Oral solids remain the dominant dosage form in the pharmaceutical market. They are used across the entire spectrum of pharmaceutical candidates and products owing to their extensive benefits including; cost-effectiveness, patient compliance, increased chemical and physical stability, convenience of handling and controlled release options. 

Insights

There is an opportunity for consolidation to help customers reduce their supplier base.

The trend of life science pharmaceutical companies partnering up with contract development and manufacturing organisations (CDMO) has grown as newer and smaller companies turn away from investing in large scale in-house production and instead outsource manufactur

Insights

Scale, breadth and depth of services will always be key drivers for pharmaceutical outsourcing, and CDMOs that can offer a wide range of technologies and expertise are uniquely placed to act as a one-stop-shop partner.